Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

The present disclosure is related to compositions and methods for the regulated and controlled expression of proteins.

The present disclosure is related to compositions and methods for the regulated and controlled expression of proteins.

Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.

Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.

Described herein are methods and pharmaceutical formulations for treating dry eye disease, increasing tear production, and reducing ocular discomfort.

Described herein are methods and pharmaceutical formulations for treating dry eye disease, increasing tear production, and reducing ocular discomfort.

Described herein are methods and pharmaceutical formulations for treating dry eye disease, increasing tear production, and reducing ocular discomfort.